GeoVax Raises $3.2M in Public Offering to Boost Cancer and Vaccine Research

GeoVax Labs, a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases, has announced a significant public offering to raise capital. The company has entered into definitive securities purchase agreements with institutional and individual investors for approximately 13.2 million units, each consisting of one share of common stock and warrants to purchase additional shares, priced at $0.245 per unit. This offering, managed by Roth Capital Partners as the exclusive placement agent, is expected to generate gross proceeds of about $3.2 million before fees and expenses. The funds will be allocated toward working capital and general corporate purposes, with the closing anticipated around December 22, 2025, pending customary conditions. The offering is conducted under an SEC-effective registration statement, and details can be accessed via the SEC's website, ensuring transparency for investors and stakeholders.

GeoVax's portfolio includes promising clinical programs such as GEO-CM04S1, a next-generation COVID-19 vaccine undergoing Phase 2 trials for immunocompromised patients and as a booster, and Gedeptin®, an oncolytic therapy for advanced head and neck cancers. Additionally, the company is advancing a vaccine targeting Mpox and smallpox, with plans to move directly to Phase 3 trials based on recent regulatory guidance. This capital infusion is crucial for supporting these innovative projects, which aim to address unmet medical needs in oncology and infectious diseases. For more information on their progress, visit www.geovax.com, where updates on clinical trials and technologies are available, highlighting the company's commitment to advancing healthcare solutions.

The offering underscores GeoVax's strategic efforts to bolster its financial position and accelerate development of its pipeline, including vaccines and therapies that could impact public health globally. By leveraging this funding, the company aims to enhance its research and operational capabilities, potentially leading to breakthroughs in treating conditions like COVID-19 and cancer. Investors and the medical community can monitor this progress through resources like the SEC's website, which provides official documentation and insights into the offering's details. This move positions GeoVax to potentially deliver transformative medical innovations, reinforcing its role in the biotechnology sector and its mission to improve patient outcomes through cutting-edge science.